Page 280 of 346: studies 2,791 to 2,800 of 3,458, newest first. Back to the MDMA overview
Science June 14, 2024 Kai Kupferschmidt 3 citations
Reeling from negative vote on MDMA-assisted PTSD therapy, researchers seek lessons for future studies.
Psychiatria June 5, 2024 Anna Stankiewicz, Jan Szewczyk, Julia Truszkowska et al. 1 citation
Drug therapies for many psychiatric conditions do not meet patients’ expectations. New agents are being sought to treat depression and anxiety disorders, among others. Scientific interest in psychoactive substances has increased over the past few decades. Recent studies provide evidence that psychedelics may find use in the treatment of a range of mental disorders. This paper describes new...
June 3, 2024 Terence Han Wei Ching preprint
Background: Systemic diversification of psychedelic research is needed, in light of interest in psychedelics for healing among Black, Indigenous, and Peoples of Color (BIPOC) and queer communities. Doing so also contributes to an inclusive evidence base, ethically meeting the anticipated demand for psychedelic treatments post-approval. Aims: Here, a primer for culturally attuned psychedelic...
Psychoactives June 2, 2024 Sean Matthew Viña 9 citations
Because psychedelics have been found to increase psychological traits like openness, mental flexibility, and interpersonal perceptiveness, some researchers believe that psychedelics could help individuals cope with the psychological effects of discrimination. However, it is still unclear whether psychedelic use can help manage the internalized stigma that deters formal mental health treatment....
Oxford Handbook of Addiction Medicine June 1, 2024
Abstract Chapter 16 of Addiction Medicine covers hallucinogens, dissociative drugs, and empathogens. Hallucinogens, also termed psychedelics, are a large and diverse group of substances, some of which occur in fungi and plants and some which are chemically synthesized. Some have psychostimulant properties as well. They include psilocybin, mescaline, dimethyltryptamine (DMT), ayahuasca, lysergic...
Forensic Science International June 1, 2024 Guillaume Drevin, Jean-Michel Gaulier, Florian Hakim et al. 21 citations
The use of 3,4-methylenedioxymethamphetamine (MDMA) in drug-facilitated sexual assault (DFSA) is not uncommon. Indeed, the effects associated with the use of this substance may lead to disinhibition. Several synthetic cathinones, such as mephedrone or methylone, also possess marked entactogenic properties. This manuscript aims to (i) report a DFSA case involving a novel cathinone derivative,...
Pharmacological Reports June 1, 2024 Katarzyna Kuczyńska, Katarzyna Bartkowska, Ruzanna Djavadian et al. 3 citations
Synthetic cathinones (SC) constitute the second most frequently abused class of new psychoactive substances. They serve as an alternative to classic psychostimulatory drugs of abuse, such as methamphetamine, cocaine, or 3,4-methylenedioxymethamphetamine (MDMA). Despite the worldwide prevalence of SC, little is known about their long-term impact on the central nervous system. Here, we examined...
Journal of Substance Use and Addiction Treatment June 1, 2024 Karl C Alcover, Abram J Lyons, Solmaz Amiri 7 citations
Adolescent drug use can result in clinically significant psychiatric outcomes later in life mitigated by targeted prevention strategies. While mean age of drug initiation has increased over time, there is little research of mean age of drug initiation among adolescents by race/ethnicity. The study used the National Survey on Drug Use and Health data (2004-2019). Sample included individuals aged...
bioRxiv May 26, 2024 Farid Aboharb, Pasha A. Davoudian, Ling-Xiao Shao et al. preprint
Psilocybin, ketamine, and MDMA are psychoactive compounds that exert behavioral effects with distinguishable but also overlapping features. The growing interest in using these compounds as therapeutics necessitates preclinical assays that can accurately screen psychedelics and related analogs. We posit that a promising approach may be to measure drug action on markers of neural plasticity in...
May 23, 2024 Daniël Hoyer
There is controversy about a causal role of serotonin (5-HT) in depression, some arguing that there is no proof for impaired brain 5-HT function in depressed patients. Major depressive disorder comes with multiple endophenotypes; not surprisingly classical antidepressants (tricyclics, MAO inhibitors, SSRIs, SNRIs) are not universally effective. Most antidepressants target the 5-HT system,...